Psoriatic Arthritis

Key clinical point: A structured 12-month weight-loss treatment with very low energy diet (VLED) showed positive effects on body weight and physical fitness without affecting the muscle strength in patients with psoriatic arthritis (PsA) and obesity.

Major finding: At month 12, the median weight loss was 16.1 kg in patients with PsA and obesity and 16.6 kg in control individuals with obesity. At month 6, the muscle strength of the lower extremities and physical functioning improved in patients with PsA and control individuals (all P < .001), which were maintained till month 12 (all P < .01). The hand-grip strength remained unchanged in both the groups.

Study details: The findings are a secondary analysis of a prospective open intervention study including 46 patients with PsA and body mass index of ≥33 kg/m² and 52 matched control individuals with obesity, all of whom received weight-loss treatment with VLED.

Disclosures: This study was supported by the Swedish state, Health and Medical Care Executive Board of the Västra Götaland, and other sources. The authors declared no conflicts of interest.

Source: Bilberg A et al. The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clin Rheumatol. 2022 (Jun 1). Doi: 10.1007/s10067-022-06164-5

Key clinical point: A structured 12-month weight-loss treatment with very low energy diet (VLED) showed positive effects on body weight and physical fitness without affecting the muscle strength in patients with psoriatic arthritis (PsA) and obesity.

Major finding: At month 12, the median weight loss was 16.1 kg in patients with PsA and obesity and 16.6 kg in control individuals with obesity. At month 6, the muscle strength of the lower extremities and physical functioning improved in patients with PsA and control individuals (all P < .001), which were maintained till month 12 (all P < .01). The hand-grip strength remained unchanged in both the groups.

Study details: The findings are a secondary analysis of a prospective open intervention study including 46 patients with PsA and body mass index of ≥33 kg/m² and 52 matched control individuals with obesity, all of whom received weight-loss treatment with VLED.

Disclosures: This study was supported by the Swedish state, Health and Medical Care Executive Board of the Västra Götaland, and other sources. The authors declared no conflicts of interest.

Source: Bilberg A et al. The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clin Rheumatol. 2022 (Jun 1). Doi: 10.1007/s10067-022-06164-5

Key clinical point: A structured 12-month weight-loss treatment with very low energy diet (VLED) showed positive effects on body weight and physical fitness without affecting the muscle strength in patients with psoriatic arthritis (PsA) and obesity.

Major finding: At month 12, the median weight loss was 16.1 kg in patients with PsA and obesity and 16.6 kg in control individuals with obesity. At month 6, the muscle strength of the lower extremities and physical functioning improved in patients with PsA and control individuals (all P < .001), which were maintained till month 12 (all P < .01). The hand-grip strength remained unchanged in both the groups.

Study details: The findings are a secondary analysis of a prospective open intervention study including 46 patients with PsA and body mass index of ≥33 kg/m² and 52 matched control individuals with obesity, all of whom received weight-loss treatment with VLED.

Disclosures: This study was supported by the Swedish state, Health and Medical Care Executive Board of the Västra Götaland, and other sources. The authors declared no conflicts of interest.

Source: Bilberg A et al. The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clin Rheumatol. 2022 (Jun 1). Doi: 10.1007/s10067-022-06164-5

Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).

Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).

Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi:  10.1155/2022/4433313

Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).

Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).

Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi:  10.1155/2022/4433313

Key clinical point: Monocyte chemotactic protein-1 (MCP-1) can serve as a biomarker for diagnosing asymptomatic diastolic dysfunction (DD) in patients with psoriatic arthritis (PsA).

Major finding: The serum MCP-1 concentration was significantly higher in patients with vs. without DD (366.6 vs. 277.5 pg/mL; P = .0017). Patients with serum MCP-1 concentration of >347.6 vs. ≤347.6 pg/mL had a 7.74-fold higher chance of developing DD (specificity 86.36%; sensitivity 55%) and showed a higher late peak diastolic mitral inflow velocity characterized by a lower E/A ratio (0.68 vs. 1.11; P = .000002).

Study details: Findings are from a random, prospective study including 63 patients with axial and peripheral PsA and without clinical manifestations of heart failure.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Bursac IU et al. Predictive value of monocyte chemoattractant protein-1 in the development of diastolic dysfunction in patients with psoriatic arthritis. Dis Markers. 2022;2022: 4433313 (Jun 3). Doi:  10.1155/2022/4433313

Key clinical point: Inflammatory and metabolic parameters, including visceral adiposity, potentially contribute to subclinical coronary artery disease (CAD) in patients with psoriatic arthritis (PsA).

Major finding: CAD was significantly associated with visceral adiposity (standardized β 0.681; P = .002), and fluorodeoxyglucose (FDG) uptake in the bone marrow (standardized β 0.488; P = .008), liver (standardized β 0.619; P < .001), spleen (standardized β 0.523; P = .004), and subcutaneous adipose tissue (standardized β 0.524; P = .003). Visceral (P = .005) and subcutaneous (P = .004) adiposity and liver FDG uptake (P = .03) were higher in patients with PsA vs. controls without PsA.

Study details: Findings are from a cross-sectional analysis of a prospective study including 39 patients with biologic-naive PsA and 56 age-sex matched controls without PsA.

Disclosures: This study was funded by the US National Institute of Allergy and Infectious Disease, the US National Heart, Lung, and Blood Institute, and National Psoriasis Foundation. N Mehta declared serving as consultant and receiving grants and other payments from several sources.

Source: Schwartz DM et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760 (Jun 2). Doi: 10.3389/fimmu.2022.909760

Key clinical point: Inflammatory and metabolic parameters, including visceral adiposity, potentially contribute to subclinical coronary artery disease (CAD) in patients with psoriatic arthritis (PsA).

Major finding: CAD was significantly associated with visceral adiposity (standardized β 0.681; P = .002), and fluorodeoxyglucose (FDG) uptake in the bone marrow (standardized β 0.488; P = .008), liver (standardized β 0.619; P < .001), spleen (standardized β 0.523; P = .004), and subcutaneous adipose tissue (standardized β 0.524; P = .003). Visceral (P = .005) and subcutaneous (P = .004) adiposity and liver FDG uptake (P = .03) were higher in patients with PsA vs. controls without PsA.

Study details: Findings are from a cross-sectional analysis of a prospective study including 39 patients with biologic-naive PsA and 56 age-sex matched controls without PsA.

Disclosures: This study was funded by the US National Institute of Allergy and Infectious Disease, the US National Heart, Lung, and Blood Institute, and National Psoriasis Foundation. N Mehta declared serving as consultant and receiving grants and other payments from several sources.

Source: Schwartz DM et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760 (Jun 2). Doi: 10.3389/fimmu.2022.909760

Key clinical point: Inflammatory and metabolic parameters, including visceral adiposity, potentially contribute to subclinical coronary artery disease (CAD) in patients with psoriatic arthritis (PsA).

Major finding: CAD was significantly associated with visceral adiposity (standardized β 0.681; P = .002), and fluorodeoxyglucose (FDG) uptake in the bone marrow (standardized β 0.488; P = .008), liver (standardized β 0.619; P < .001), spleen (standardized β 0.523; P = .004), and subcutaneous adipose tissue (standardized β 0.524; P = .003). Visceral (P = .005) and subcutaneous (P = .004) adiposity and liver FDG uptake (P = .03) were higher in patients with PsA vs. controls without PsA.

Study details: Findings are from a cross-sectional analysis of a prospective study including 39 patients with biologic-naive PsA and 56 age-sex matched controls without PsA.

Disclosures: This study was funded by the US National Institute of Allergy and Infectious Disease, the US National Heart, Lung, and Blood Institute, and National Psoriasis Foundation. N Mehta declared serving as consultant and receiving grants and other payments from several sources.

Source: Schwartz DM et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760 (Jun 2). Doi: 10.3389/fimmu.2022.909760

Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.

Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.

Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719

Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.

Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.

Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719

Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.

Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.

Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719

Key clinical point: The prevalence of crystals in the synovial fluid was higher in patients with psoriatic arthritis (PsA) than in those with gonarthrosis and indicated increased disease activity and declining physical abilities in patients with PsA.

Major finding: Synovial fluid crystals were present in a significantly higher proportion of patients with PsA vs. gonarthrosis (23.7% vs. 0%; P < .001), with the presence of crystals being associated with an increased odds of severe pain (odds ratio [OR] 157.25), high disease activity (OR 15.96), and severe disability (OR 13.60; all P < .001).

Study details: Findings are from a retrospective case-control study including 156 patients with PsA and 50 patients with gonarthrosis.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Geneva-Popova M et al. Assessment of crystals in the synovial fluid of psoriatic arthritis patients in relation to disease activity. Diagnostics (Basel). 2022;12(5):1260 (May 18). Doi:  10.3390/diagnostics12051260

Key clinical point: The prevalence of crystals in the synovial fluid was higher in patients with psoriatic arthritis (PsA) than in those with gonarthrosis and indicated increased disease activity and declining physical abilities in patients with PsA.

Major finding: Synovial fluid crystals were present in a significantly higher proportion of patients with PsA vs. gonarthrosis (23.7% vs. 0%; P < .001), with the presence of crystals being associated with an increased odds of severe pain (odds ratio [OR] 157.25), high disease activity (OR 15.96), and severe disability (OR 13.60; all P < .001).

Study details: Findings are from a retrospective case-control study including 156 patients with PsA and 50 patients with gonarthrosis.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Geneva-Popova M et al. Assessment of crystals in the synovial fluid of psoriatic arthritis patients in relation to disease activity. Diagnostics (Basel). 2022;12(5):1260 (May 18). Doi:  10.3390/diagnostics12051260

Key clinical point: The prevalence of crystals in the synovial fluid was higher in patients with psoriatic arthritis (PsA) than in those with gonarthrosis and indicated increased disease activity and declining physical abilities in patients with PsA.

Major finding: Synovial fluid crystals were present in a significantly higher proportion of patients with PsA vs. gonarthrosis (23.7% vs. 0%; P < .001), with the presence of crystals being associated with an increased odds of severe pain (odds ratio [OR] 157.25), high disease activity (OR 15.96), and severe disability (OR 13.60; all P < .001).

Study details: Findings are from a retrospective case-control study including 156 patients with PsA and 50 patients with gonarthrosis.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Geneva-Popova M et al. Assessment of crystals in the synovial fluid of psoriatic arthritis patients in relation to disease activity. Diagnostics (Basel). 2022;12(5):1260 (May 18). Doi:  10.3390/diagnostics12051260

Key clinical point: Patients with psoriatic arthritis (PsA) who had a personal history of psoriasis (pPsA) or a family history of psoriasis and current psoriatic lesions (fPsA/PSO) showed a higher disease activity (DA) and more severe axial joint destruction than those with merely a family history of psoriasis (fPsA).

Major finding: Patients with fPsA/PSO vs. fPsA had higher Disease Activity (DA) Index for PsA (DAPSA; 21.94 vs. 18.41; P = .046) and Bath Ankylosing Spondylitis DA Index (BASDAI; 4.09 vs. 3.74; P = .031) scores and more severe sacroiliitis (odds ratio [OR] 0.508; P = .037). The DAPSA (P = .927) and BASDAI (P = .716) scores were similar in patients with pPsA and fPsA/PSO.

Study details: Findings are from a prospective single-center, cross-sectional study including 296 patients with PsA, of which 145 had pPsA, 96 had fPsA, and 55 had fPsA/PSO.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Li S-S et al. Exploring the association between history of psoriasis (PSO) and disease activity in patients with psoriatic arthritis (PsA). Rheumatol Ther. 2022 (May 17). Doi: 10.1007/s40744-022-00455-8

Key clinical point: Patients with psoriatic arthritis (PsA) who had a personal history of psoriasis (pPsA) or a family history of psoriasis and current psoriatic lesions (fPsA/PSO) showed a higher disease activity (DA) and more severe axial joint destruction than those with merely a family history of psoriasis (fPsA).

Major finding: Patients with fPsA/PSO vs. fPsA had higher Disease Activity (DA) Index for PsA (DAPSA; 21.94 vs. 18.41; P = .046) and Bath Ankylosing Spondylitis DA Index (BASDAI; 4.09 vs. 3.74; P = .031) scores and more severe sacroiliitis (odds ratio [OR] 0.508; P = .037). The DAPSA (P = .927) and BASDAI (P = .716) scores were similar in patients with pPsA and fPsA/PSO.

Study details: Findings are from a prospective single-center, cross-sectional study including 296 patients with PsA, of which 145 had pPsA, 96 had fPsA, and 55 had fPsA/PSO.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Li S-S et al. Exploring the association between history of psoriasis (PSO) and disease activity in patients with psoriatic arthritis (PsA). Rheumatol Ther. 2022 (May 17). Doi: 10.1007/s40744-022-00455-8

Key clinical point: Patients with psoriatic arthritis (PsA) who had a personal history of psoriasis (pPsA) or a family history of psoriasis and current psoriatic lesions (fPsA/PSO) showed a higher disease activity (DA) and more severe axial joint destruction than those with merely a family history of psoriasis (fPsA).

Major finding: Patients with fPsA/PSO vs. fPsA had higher Disease Activity (DA) Index for PsA (DAPSA; 21.94 vs. 18.41; P = .046) and Bath Ankylosing Spondylitis DA Index (BASDAI; 4.09 vs. 3.74; P = .031) scores and more severe sacroiliitis (odds ratio [OR] 0.508; P = .037). The DAPSA (P = .927) and BASDAI (P = .716) scores were similar in patients with pPsA and fPsA/PSO.

Study details: Findings are from a prospective single-center, cross-sectional study including 296 patients with PsA, of which 145 had pPsA, 96 had fPsA, and 55 had fPsA/PSO.

Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Li S-S et al. Exploring the association between history of psoriasis (PSO) and disease activity in patients with psoriatic arthritis (PsA). Rheumatol Ther. 2022 (May 17). Doi: 10.1007/s40744-022-00455-8

Key clinical point: Difficult-to-treat (D2T) patients with psoriatic arthritis (PsA) have a higher prevalence of fibromyalgia, higher body mass index (BMI), and more comorbidities than non-D2T patients with PsA.

Major finding: The potential D2T vs. non-D2T patients had a significantly higher prevalence of fibromyalgia (22.9% vs. 7.2%; P = .022) and a higher median BMI (27.7 vs. 25.7; P = .032), Functional Comorbidity Index value (1 vs. 0; P = .021), disease activity index value (17.2 vs. 7.1; P < .01), pain level (7 vs. 2.5; P < .01), and Health Assessment Questionnaire Disability Index value (1 vs. 0.25; P < .001). Treatment failure with ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs was observed in 100% vs. 8.5% of D2T vs. non-D2T patients, respectively.

Study details: This retrospective analysis of a longitudinal cohort included 106 patients with PsA, of which 36 patients were considered potential D2T candidates.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Clinical characteristics of potential “difficult-to-treat” patients with psoriatic arthritis: A retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022 May 25. doi: 10.1007/s40744-022-00461-w.

Key clinical point: Difficult-to-treat (D2T) patients with psoriatic arthritis (PsA) have a higher prevalence of fibromyalgia, higher body mass index (BMI), and more comorbidities than non-D2T patients with PsA.

Major finding: The potential D2T vs. non-D2T patients had a significantly higher prevalence of fibromyalgia (22.9% vs. 7.2%; P = .022) and a higher median BMI (27.7 vs. 25.7; P = .032), Functional Comorbidity Index value (1 vs. 0; P = .021), disease activity index value (17.2 vs. 7.1; P < .01), pain level (7 vs. 2.5; P < .01), and Health Assessment Questionnaire Disability Index value (1 vs. 0.25; P < .001). Treatment failure with ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs was observed in 100% vs. 8.5% of D2T vs. non-D2T patients, respectively.

Study details: This retrospective analysis of a longitudinal cohort included 106 patients with PsA, of which 36 patients were considered potential D2T candidates.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Clinical characteristics of potential “difficult-to-treat” patients with psoriatic arthritis: A retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022 May 25. doi: 10.1007/s40744-022-00461-w.

Key clinical point: Difficult-to-treat (D2T) patients with psoriatic arthritis (PsA) have a higher prevalence of fibromyalgia, higher body mass index (BMI), and more comorbidities than non-D2T patients with PsA.

Major finding: The potential D2T vs. non-D2T patients had a significantly higher prevalence of fibromyalgia (22.9% vs. 7.2%; P = .022) and a higher median BMI (27.7 vs. 25.7; P = .032), Functional Comorbidity Index value (1 vs. 0; P = .021), disease activity index value (17.2 vs. 7.1; P < .01), pain level (7 vs. 2.5; P < .01), and Health Assessment Questionnaire Disability Index value (1 vs. 0.25; P < .001). Treatment failure with ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs was observed in 100% vs. 8.5% of D2T vs. non-D2T patients, respectively.

Study details: This retrospective analysis of a longitudinal cohort included 106 patients with PsA, of which 36 patients were considered potential D2T candidates.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Clinical characteristics of potential “difficult-to-treat” patients with psoriatic arthritis: A retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022 May 25. doi: 10.1007/s40744-022-00461-w.

Key clinical point: Golimumab reduced disease activity and improved work productivity, activity, and the quality of life (QoL) in patients with psoriatic arthritis (PsA).

Major finding: At 24 months after golimumab initiation, there was significant decrease in mean Clinical Disease Activity Index (−21.7; P < .0001), along with improvement in total work productivity impairment (P = .0186), presenteeism (P = .0007), activity impairment (P < .0001), and mean QoL (−8.3; P < .0001) scores.

Study details: Findings are from a prospective study including patients with PsA (n = 69), rheumatoid arthritis (n = 95), and axial spondyloarthritis (n = 69) who initiated golimumab; of these 110 patients were followed-up for 24 months.

Disclosures: This study was funded by MSD Austria. The authors declared no conflicts of interest.

Source: Dejaco C et al. A prospective study to evaluate the impact of golimumab therapy on work productivity and activity, and quality of life in patients with rheumatoid arthritis, psoriasis arthritis and axial spondyloarthritis in a real life setting in Austria: The GO-ACTIVE study. Front Med. 2022;9:881943 (Jun 2). Doi: 10.3389/fmed.2022.881943

Key clinical point: Golimumab reduced disease activity and improved work productivity, activity, and the quality of life (QoL) in patients with psoriatic arthritis (PsA).

Major finding: At 24 months after golimumab initiation, there was significant decrease in mean Clinical Disease Activity Index (−21.7; P < .0001), along with improvement in total work productivity impairment (P = .0186), presenteeism (P = .0007), activity impairment (P < .0001), and mean QoL (−8.3; P < .0001) scores.

Study details: Findings are from a prospective study including patients with PsA (n = 69), rheumatoid arthritis (n = 95), and axial spondyloarthritis (n = 69) who initiated golimumab; of these 110 patients were followed-up for 24 months.

Disclosures: This study was funded by MSD Austria. The authors declared no conflicts of interest.

Source: Dejaco C et al. A prospective study to evaluate the impact of golimumab therapy on work productivity and activity, and quality of life in patients with rheumatoid arthritis, psoriasis arthritis and axial spondyloarthritis in a real life setting in Austria: The GO-ACTIVE study. Front Med. 2022;9:881943 (Jun 2). Doi: 10.3389/fmed.2022.881943

Key clinical point: Golimumab reduced disease activity and improved work productivity, activity, and the quality of life (QoL) in patients with psoriatic arthritis (PsA).

Major finding: At 24 months after golimumab initiation, there was significant decrease in mean Clinical Disease Activity Index (−21.7; P < .0001), along with improvement in total work productivity impairment (P = .0186), presenteeism (P = .0007), activity impairment (P < .0001), and mean QoL (−8.3; P < .0001) scores.

Study details: Findings are from a prospective study including patients with PsA (n = 69), rheumatoid arthritis (n = 95), and axial spondyloarthritis (n = 69) who initiated golimumab; of these 110 patients were followed-up for 24 months.

Disclosures: This study was funded by MSD Austria. The authors declared no conflicts of interest.

Source: Dejaco C et al. A prospective study to evaluate the impact of golimumab therapy on work productivity and activity, and quality of life in patients with rheumatoid arthritis, psoriasis arthritis and axial spondyloarthritis in a real life setting in Austria: The GO-ACTIVE study. Front Med. 2022;9:881943 (Jun 2). Doi: 10.3389/fmed.2022.881943

Key clinical point: A higher proportion of patients with psoriatic arthritis (PsA) receiving 15 mg upadacitinib achieved low disease activity (LDA) or remission after the first 6 months of treatment, with the difference being visible even after 1 year of treatment, compared to those who received a placebo.

Major finding: At week 24, a higher proportion of patients receiving 15 mg upadacitinib vs. placebo achieved Disease Activity in PsA LDA (range 35%-48% vs. 4%-16%; P < .05) and remission (range 7%-11% vs. 0%-3%; P < .05), with the responses sustained until 56 weeks.

Study details: This was a post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials including 1386 adults with PsA and prior inadequate response/intolerance to ≥1 non-biologic or biologic disease-modifying antirheumatic drugs who were randomly assigned to receive upadacitinib (15 or 30 mg), adalimumab, or placebo.

Disclosures: This study was funded by AbbVie, Inc. Four authors declared being current or former employees or stockholders of AbbVie, and other authors reported ties with various sources.

Source: Mease P et al. Disease control with upadacitinib in patients with psoriatic arthritis: A post hoc analysis of the randomized, placebo-controlled SELECT-PsA 1 and 2 phase 3 trials. Rheumatol Ther. 2022 (May 23). Doi: 10.1007/s40744-022-00449-6

Key clinical point: A higher proportion of patients with psoriatic arthritis (PsA) receiving 15 mg upadacitinib achieved low disease activity (LDA) or remission after the first 6 months of treatment, with the difference being visible even after 1 year of treatment, compared to those who received a placebo.

Major finding: At week 24, a higher proportion of patients receiving 15 mg upadacitinib vs. placebo achieved Disease Activity in PsA LDA (range 35%-48% vs. 4%-16%; P < .05) and remission (range 7%-11% vs. 0%-3%; P < .05), with the responses sustained until 56 weeks.

Study details: This was a post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials including 1386 adults with PsA and prior inadequate response/intolerance to ≥1 non-biologic or biologic disease-modifying antirheumatic drugs who were randomly assigned to receive upadacitinib (15 or 30 mg), adalimumab, or placebo.

Disclosures: This study was funded by AbbVie, Inc. Four authors declared being current or former employees or stockholders of AbbVie, and other authors reported ties with various sources.

Source: Mease P et al. Disease control with upadacitinib in patients with psoriatic arthritis: A post hoc analysis of the randomized, placebo-controlled SELECT-PsA 1 and 2 phase 3 trials. Rheumatol Ther. 2022 (May 23). Doi: 10.1007/s40744-022-00449-6

Key clinical point: A higher proportion of patients with psoriatic arthritis (PsA) receiving 15 mg upadacitinib achieved low disease activity (LDA) or remission after the first 6 months of treatment, with the difference being visible even after 1 year of treatment, compared to those who received a placebo.

Major finding: At week 24, a higher proportion of patients receiving 15 mg upadacitinib vs. placebo achieved Disease Activity in PsA LDA (range 35%-48% vs. 4%-16%; P < .05) and remission (range 7%-11% vs. 0%-3%; P < .05), with the responses sustained until 56 weeks.

Study details: This was a post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials including 1386 adults with PsA and prior inadequate response/intolerance to ≥1 non-biologic or biologic disease-modifying antirheumatic drugs who were randomly assigned to receive upadacitinib (15 or 30 mg), adalimumab, or placebo.

Disclosures: This study was funded by AbbVie, Inc. Four authors declared being current or former employees or stockholders of AbbVie, and other authors reported ties with various sources.

Source: Mease P et al. Disease control with upadacitinib in patients with psoriatic arthritis: A post hoc analysis of the randomized, placebo-controlled SELECT-PsA 1 and 2 phase 3 trials. Rheumatol Ther. 2022 (May 23). Doi: 10.1007/s40744-022-00449-6

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) achieved resolution of enthesitis within a year of initiating nonsteroidal anti-inflammatory drugs (NSAID) or disease-modifying antirheumatic drugs (DMARD), although the odds were lower in patients with high joint disease activity at baseline.

Major finding: Complete resolution of enthesitis was achieved by 86.12% of patients within a mean period of 8.73 months from therapy initiation, with higher joint activity at baseline being associated with a lower chance of enthesitis resolution (odds ratio 0.97; P = .01).

Study details: Findings are from a retrospective analysis of prospectively collected data of 526 patients with PsA and enthesitis who received no treatment/only NSAID (n = 142), conventional DMARD ± NSAID but without targeted DMARD (n = 196), or targeted DMARD with or without other medications (n = 188).

Disclosures: Dr. Mathew and Dr. Chandran received funding from the National Psoriasis Foundation and University of Toronto, respectively. The authors declared no conflicts of interest.

Source: Mathew AJ et al. Effectiveness of disease modifying anti-rheumatic drugs for enthesitis in a prospective longitudinal psoriatic arthritis cohort. J Rheumatol. 2022 (Jun 1). Doi: 10.3899/jrheum.211231

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) achieved resolution of enthesitis within a year of initiating nonsteroidal anti-inflammatory drugs (NSAID) or disease-modifying antirheumatic drugs (DMARD), although the odds were lower in patients with high joint disease activity at baseline.

Major finding: Complete resolution of enthesitis was achieved by 86.12% of patients within a mean period of 8.73 months from therapy initiation, with higher joint activity at baseline being associated with a lower chance of enthesitis resolution (odds ratio 0.97; P = .01).

Study details: Findings are from a retrospective analysis of prospectively collected data of 526 patients with PsA and enthesitis who received no treatment/only NSAID (n = 142), conventional DMARD ± NSAID but without targeted DMARD (n = 196), or targeted DMARD with or without other medications (n = 188).

Disclosures: Dr. Mathew and Dr. Chandran received funding from the National Psoriasis Foundation and University of Toronto, respectively. The authors declared no conflicts of interest.

Source: Mathew AJ et al. Effectiveness of disease modifying anti-rheumatic drugs for enthesitis in a prospective longitudinal psoriatic arthritis cohort. J Rheumatol. 2022 (Jun 1). Doi: 10.3899/jrheum.211231

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) achieved resolution of enthesitis within a year of initiating nonsteroidal anti-inflammatory drugs (NSAID) or disease-modifying antirheumatic drugs (DMARD), although the odds were lower in patients with high joint disease activity at baseline.

Major finding: Complete resolution of enthesitis was achieved by 86.12% of patients within a mean period of 8.73 months from therapy initiation, with higher joint activity at baseline being associated with a lower chance of enthesitis resolution (odds ratio 0.97; P = .01).

Study details: Findings are from a retrospective analysis of prospectively collected data of 526 patients with PsA and enthesitis who received no treatment/only NSAID (n = 142), conventional DMARD ± NSAID but without targeted DMARD (n = 196), or targeted DMARD with or without other medications (n = 188).

Disclosures: Dr. Mathew and Dr. Chandran received funding from the National Psoriasis Foundation and University of Toronto, respectively. The authors declared no conflicts of interest.

Source: Mathew AJ et al. Effectiveness of disease modifying anti-rheumatic drugs for enthesitis in a prospective longitudinal psoriatic arthritis cohort. J Rheumatol. 2022 (Jun 1). Doi: 10.3899/jrheum.211231